Efficacy and safety of opioid therapy guided by pharmacogenetics: a systematic review

References

• 1. Goldberg DS, McGee SJ. Pain as a global public health priority. BMC Public Health 11, 700 (2011).
  MedlineGoogle Scholar
• 2. Treede RD, Rief W, Barke A et al. A classification of chronic pain for ICD-11. Pain 156(6), 1003–1007 (2015).
  MedlineGoogle Scholar
• 3. Nicholson B. Responsible prescribing of opioids for the management of chronic pain. Drugs 63(1), 17–32 (2003).
  MedlineGoogle Scholar
• 4. Singh A, Zai C, Mohiuddin AG, Kennedy JL. The pharmacogenetics of opioid treatment for pain management. J. Psychopharmacol. 34(11), 1200–1209 (2020).
  Medline CASGoogle Scholar
• 5. WHO. Opioid overdose. https://apps.who.int/iris/handle/10665/64993?locale-attribute=es&
  Google Scholar
• 6. Corli O, Damia G, Galli F, Verrastro C, Broggini M. Lack of efficacy: when opioids do not achieve analgesia from the beginning of treatment in cancer patients. Cancer Manag. Res. 11 (2019).
  MedlineGoogle Scholar
• 7. Smith HS. Opioid metabolism. Mayo Clin. Proc. 84(7), 613–624 (2009).
  Medline CASGoogle Scholar
• 8. Cregg R, Russo G, Gubbay A, Branford R, Sato H. Pharmacogenetics of analgesic drugs. Br. J. Pain 7(4), 189–208 (2013).
  MedlineGoogle Scholar
• 9. Matic M, De Wildt SN, Tibboel D, Van Schaik RHN. Analgesia and opioids: a pharmacogenetics shortlist for implementation in clinical practice. Clin. Chem. 63(7), 1204–1213 (2017).
  Medline CASGoogle Scholar
• 10. Ruaño G, Kost JA. Fundamental considerations for genetically-guided pain management with opioids based on cyp2d6 and oprm1 polymorphisms. Pain Physician 21(6), E611–E621 (2018).
  MedlineGoogle Scholar
• 11. Caudle KE, Sangkuhl K, Whirl-Carrillo M et al. Standardizing CYP2D6 genotype to phenotype translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clin. Transl. Sci. 13(1), 116–124 (2020).
  MedlineGoogle Scholar
• 12. PharmGKB. Gene-specific information tables for CYP2D6. https://www.pharmgkb.org/page/cyp2d6RefMaterials
  Google Scholar
• 13. Crews KR, Gaedigk A, Dunnenberger HM et al. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 Update. Clin. Pharmacol. Ther. 95(4), 376–382 (2014).
  Medline CASGoogle Scholar
• 14. Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Steven Leeder J. Prediction of CYP2D6 phenotype from genotype across world populations. Genet. Med. 19(1), 69–76 (2017).
  MedlineGoogle Scholar
• 15. Drewes AM, Jensen RD, Nielsen LM et al. Differences between opioids: pharmacological, experimental, clinical and economical perspectives. Br. J. Clin. Pharmacol. 75(1), 60–78 (2013).
  Medline CASGoogle Scholar
• 16. Yu Z, Wen L, Shen X, Zhang H. Effects of the OPRM1 A118G polymorphism (rs1799971) on opioid analgesia in cancer pain: a systematic review and meta-analysis. Clin. J. Pain 35(1), 77–86 (2019).
  MedlineGoogle Scholar
• 17. Hu B, Zhang X, Xu G et al. Association between COMT polymorphism Val158Met and opioid consumption in patients with postoperative pain: a meta-analysis. NeuroSignals 26(1), 11–21 (2019).
  Google Scholar
• 18. Hwang IC, Park JY, Myung SK, Ahn HY, Fukuda KI, Liao Q. OPRM1 A118G gene variant and postoperative opioid requirement: a systematic review and meta-analysis. Anesthesiology 121(4), 825–834 (2014).
  MedlineGoogle Scholar
• 19. Henker RA, Lewis A, Dai F et al. The associations between OPRM1 and COMT genotypes and postoperative pain, opioid use, and opioid-induced sedation. Biol. Res. Nurs. 15(3), 309–317 (2013).
  Medline CASGoogle Scholar
• 20. Cavallari LH, Van Driest SL, Prows CA et al. Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing. Genet. Med. 21(10), 2255–2263 (2019).
  MedlineGoogle Scholar
• 21. Frigon MP, Blackburn MÈ, Dubois-Bouchard C, Gagnon AL, Tardif S, Tremblay K. Pharmacogenetic testing in primary care practice: opinions of physicians, pharmacists and patients. Pharmacogenomics 20(8), 589–598 (2019).
  CASGoogle Scholar
• 22. Crews K, Monte A, Huddart R. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy. Clin. Pharmacol. Ther. (2020). https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/cpt.2149
  MedlineGoogle Scholar
• 23. Cochrane. Cochrane Handbook for Systematic Reviews of Interventions. https://training.cochrane.org/handbook/current
  Google Scholar
• 24. Moher D, Liberati A, Tetzlaff J et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 6(7), e123–130 (2009).
  Google Scholar
• 25. Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 6(7), e1000100 (2009).
  MedlineGoogle Scholar
• 26. Rodriguez Cairoli F. Is opioid therapy guided by pharmacogenetics safer and more efficacious than usual opioid treatment for pain management?. PROSPERO (2019). https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=150313
  Google Scholar
• 27. Covidence. Covidence. https://www.covidence.org
  Google Scholar
• 28. Cochrane. RoB 2: a revised Cochrane risk-of-bias tool for randomized trials. https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-risk-bias-tool-randomized-trials
  Google Scholar
• 29. Cochrane. ROBINS-I tool. https://methods.cochrane.org/methods-cochrane/robins-i-tool
  Google Scholar
• 30. NCT03455751. Precision pain management for major abdominal surgery in colorectal surgery. (2018). https://clinicaltrials.gov/show/NCT03455751
  Google Scholar
• 31. NCT04445792. A depression and opioid pragmatic trial in pharmacogenetics (DCRI coordinating center) (ADOPT PGx). (2020). https://clinicaltrials.gov/ct2/show/NCT04445792
  Google Scholar
• 32. NCT03924557. Genotype-guided supportive care in symptom treatment of cancer patients. (2019). ClinicalTrials.gov
  Google Scholar
• 33. Truong TM, Apfelbaum J, Shahul S et al. The ImPreSS Trial: implementation of point-of-care pharmacogenomic decision support in perioperative care. Clin. Pharmacol. Ther. 106(6), 1179–1183 (2019).
  MedlineGoogle Scholar
• 34. NCT02605343. Prospective observational clinical study to evaluate patient outcomes following pharmacogenetic testing of patients undergoing elective surgical procedures. https://clinicaltrials.gov/ct2/show/NCT02605343
  Google Scholar
• 35. NCT02599870. Clinical study to evaluate clinical impact of PGx-guided treatment for patients undergoing elective spinal surgical procedures. (2015). https://clinicaltrials.gov/ct2/show/NCT02599870
  Google Scholar
• 36. Moretti ME, Lato DF, Berger H, Koren G, Ito S, Ungar WJ. A cost-effectiveness analysis of maternal CYP2D6 genetic testing to guide treatment for postpartum pain and avert infant adverse events. Pharmacogenomics J. 18(3), 391–397 (2018).
  Medline CASGoogle Scholar
• 37. NCT01731873. Patient controlled analgesia pharmacogenetic study. (2012). https://clinicaltrials.gov/ct2/show/NCT01731873
  Google Scholar
• 38. AC B, D K, BA B et al. Impact of preemptive CYP2D6 genotyping: results from an institutional pharmacogenomics program. Clin. Pharmacol. Ther. 103, S26 (2018).
  Google Scholar
• 39. Fulton CR, Zang Y, Desta Z et al. Drug-gene and drug-drug interactions associated with tramadol and codeine therapy in the INGENIOUS trial. Pharmacogenomics 20(6), 397–408 (2019).
  CASGoogle Scholar
• 40. Sharma M, Kantorovich S, Lee C et al. An observational study of the impact of genetic testing for pain perception in the clinical management of chronic non-cancer pain. J. Psychiatr. Res. 65–72 (2017).
  MedlineGoogle Scholar
• 41. Palada V, Kaunisto MA, Kalso E. Genetics and genomics in postoperative pain and analgesia. Curr. Opin. Anaesthesiol. 31(5), 569–574 (2018).
  Medline CASGoogle Scholar
• 42. Yang GS, Barnes NM, Lyon DE, Dorsey SG. Genetic variants associated with cancer pain and response to opioid analgesics: implications for precision pain management. Semin. Oncol. Nurs. 35(3), 291–299 (2019).
  MedlineGoogle Scholar
• 43. Smith DM, Weitzel KW, Cavallari LH, Elsey AR, Schmidt SO. Clinical application of pharmacogenetics in pain management. Per. Med. 15(2), 117–126 (2018).
  CASGoogle Scholar
• 44. Lloyd RA, Hotham E, Hall C, Williams M, Suppiah V. Pharmacogenomics and patient treatment parameters to opioid treatment in chronic pain: a focus on morphine, oxycodone, tramadol, and fentanyl. Pain Med. (USA) 18(12), 2369–2387 (2017).
  MedlineGoogle Scholar
• 45. Dorfman R, London Z, Metias M, Kabakchiev B, Mukerjee G, Moser A. Individualized medication management in ontario long-term care clinical impact on management of depression, pain, and dementia. J. Am. Med. Dir. Assoc. 21(6), 823–829 (2020).
  MedlineGoogle Scholar
• 46. Mosley SA, Hicks JK, Portman DG et al. Design and rational for the precision medicine guided treatment for cancer pain pragmatic clinical trial. Contemp. Clin. Trials. 68 (2018).
  MedlineGoogle Scholar
• 47. Fenech A, Portman D, Chang Y, Smith J, Donovan K. Pilot study to assess the feasibility and acceptability of pharmacogenomics research for pain control in palliative care. Psychooncology 26, 71 (2017).
  Google Scholar
• 48. Smith DM, Weitzel KW, Elsey AR et al. CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial. Genet. Med. 21(8), 1842–1850 (2019).
  Medline CASGoogle Scholar
• 49. Senagore AJ, Champagne BJ, Dosokey E et al. Pharmacogenetics-guided analgesics in major abdominal surgery: further benefits within an enhanced recovery protocol. Am. J. Surg. 213(3), 467–472 (2017).
  MedlineGoogle Scholar
• 50. Thomas CD, Parvataneni HK, Gray CF et al. A hybrid implementation-effectiveness randomized trial of CYP2D6-guided postoperative pain management. Genet. Med. 621–628 (2021).
  MedlineGoogle Scholar
• 51. Patel JN, Boselli D, Hamadeh IS et al. Pain management using clinical pharmacy assessments with and without pharmacogenomics in an Oncology Palliative Medicine Clinic. JCO Oncol. Pract. 16(2), e166–e174 (2020).
  MedlineGoogle Scholar
• 52. Hamilton WG, Gargiulo JM, Parks NL. Using pharmacogenetics to structure individual pain management protocols in total knee arthroplasty: a randomized pilot study. Bone Jt J. 102-B(6), 73–78 (2020).
  MedlineGoogle Scholar
• 53. Baber M, Bapat P, Nichol G, Koren G. The pharmacogenetics of opioid therapy in the management of postpartum pain: a systematic review. Pharmacogenomics 17(1), 75–93 (2016).
  CASGoogle Scholar
• 54. Ahmed S, Choudhry Z, Bhatti JA. Impact of genetic polymorphisms on opioid misuse: a scoping review. Pharmacogenomics 20(9), 685–703 (2019).
  CASGoogle Scholar
• 55. Wu SB, Cai LN, Yang XH et al. Impact of CYP2D6 polymorphisms on postoperative fentanyl analgesia in gastric cancer patients. Genet. Test. Mol. Biomarkers 19(5), 248–252 (2015).
  Medline CASGoogle Scholar
• 56. Yamamoto PA, Conchon Costa AC, Lauretti GR, De Moraes NV. Pharmacogenomics in chronic pain therapy: from disease to treatment and challenges for clinical practice. Pharmacogenomics 20(13), 971–982 (2019).
  CASGoogle Scholar
• 57. Clinicaltrial.gov. Comparison of standard opioid prescription versus prescription guided by pharmacogenetic analysis in patients with non-cancerous chronic pain. (2018). https://www.clinicaltrials.gov/ct2/show/NCT03498014
  Google Scholar
• 58. Kheiri B, Osman M, Abdalla A et al. CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: a meta-analysis of randomized clinical trials. Catheter. Cardiovasc. Interv. 93(7), 1246–1252 (2019).
  MedlineGoogle Scholar